drugset / Trial / NCT00285779
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
Phase 2
Terminated
27 enrolled
Stanford University
Emory University · collabFivenson, David, M.D. · collabIcahn School of Medicine at Mount Sinai · collabOregon Health and Science University · collabThe Cleveland Clinic · collabTufts Medical Center · collabUniversity Hospitals Cleveland Medical Center · collabUniversity of Louisville · collabUniversity of Michigan · collabWake Forest University Health Sciences · collabWright State University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose is to assess the response of subjects to etanercept (as compared to placebo) in treating the physical signs of mucosal and cutaneous lichen planus. The investigators also wish to assess the effect of etanercept on disease-related itching, pain, and serious adverse events in patients with lichen planus.
Timeline
- Start
- 2006-08
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 25 mg | Subcutaneous |
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |